×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VERU – veru inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VERU
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/22
06:08 am
veru
Veru (VERU) had its "sell (e+)" rating reaffirmed by Weiss Ratings.
Neutral
Report
Veru (VERU) had its "sell (e+)" rating reaffirmed by Weiss Ratings.
3/9
08:51 am
veru
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss [Yahoo! Finance]
Low
Report
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss [Yahoo! Finance]
3/9
08:30 am
veru
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Low
Report
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
2/19
08:30 am
veru
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/12
10:35 am
veru
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
Medium
Report
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
2/11
01:56 pm
veru
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript [Seeking Alpha]
2/11
06:30 am
veru
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
Neutral
Report
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
2/4
08:30 am
veru
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
Low
Report
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/17
04:58 pm
veru
Form SCHEDULE 13G VERU INC. Filed by: Alyeska Investment Group, L.P.
Medium
Report
Form SCHEDULE 13G VERU INC. Filed by: Alyeska Investment Group, L.P.
2/11
10:32 am
veru
Form 10-Q VERU INC. For: Dec 31
Medium
Report
Form 10-Q VERU INC. For: Dec 31
2/11
07:00 am
veru
Form 8-K VERU INC. For: Feb 11
Medium
Report
Form 8-K VERU INC. For: Feb 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/13
Is Paratek Pharmaceuticals Inc (PRTK) Going to Burn These Hedge Funds? [Yahoo! Finance News]
25.0%
12/13 Veru Inc (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.50 price target on the stock. 12.1%
6/4 Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA 8.8%
1/21 Veru Inc (NASDAQ: VERU) had its "reduce" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock, up previously from $4.50. 8.8%
2/19 Form 4 VERU INC. For: Feb 19 Filed by: Socorro Jesus 7.8%
9/28 Veru Inc (NASDAQ: VERU) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. 7.5%
8/28 Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York 6.6%
3/4 Veru Inc (NASDAQ: VERU) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 5.1%
5/3 Form 4 VERU INC. For: May 01 Filed by: STEINER MITCHELL SHUSTER 4.1%
11/2 Veru Inc (NASDAQ: VERU) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 4.1%
12/13 Veru Inc (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.50 price target on the stock. 12.1%
6/4 Veru Adds Breakthrough Novel Androgen Deprivation Therapy Formulation to its Advancing Prostate Cancer Drug Pipeline Following Successful Meeting with FDA 8.8%
1/21 Veru Inc (NASDAQ: VERU) had its "reduce" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock, up previously from $4.50. 8.8%
2/19 Form 4 VERU INC. For: Feb 19 Filed by: Socorro Jesus 7.8%
9/28 Veru Inc (NASDAQ: VERU) had its "hold" rating re-affirmed by analysts at Zacks Investment Research. 7.5%
8/28 Veru to Participate at Three Upcoming Healthcare Investor Conferences in New York 6.6%
3/4 Veru Inc (NASDAQ: VERU) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. 5.1%
5/3 Form 4 VERU INC. For: May 01 Filed by: STEINER MITCHELL SHUSTER 4.1%
11/2 Veru Inc (NASDAQ: VERU) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. 4.1%
TOP News Decliners
8/27
Veru to Ring NASDAQ Closing Bell on September 4th to Kick Off National Prostate Cancer Awareness Month
-9.5%
8/8 Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter -9.4%
12/12 Form 8-K VERU INC. For: Dec 12 -7.7%
8/9 Veru Inc (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.50 price target on the stock. -7.5%
5/15 Q2/2019 3/31/2019 EPS -0.060 ZacksConsensus -0.050 ActVsEst (0.010) - Miss -7.1%
6/6 Veru Inc (NASDAQ: VERU) was given a new $5.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -6.3%
8/1 Veru to Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call on August 8th -6.3%
1/28 Form DEF 14A VERU INC. For: Mar 24 -5.4%
1/25 Veru Inc (NASDAQ: VERU) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -5.4%
1/13 Veru's experimental drug reduces hot flashes in men in mid-stage study [Reuters (UK)] -3.9%
8/8 Veru Reports Higher Net Revenues and Gross Profit for its Fiscal 2019 Third Quarter -9.4%
12/12 Form 8-K VERU INC. For: Dec 12 -7.7%
8/9 Veru Inc (NASDAQ: VERU) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.50 price target on the stock. -7.5%
5/15 Q2/2019 3/31/2019 EPS -0.060 ZacksConsensus -0.050 ActVsEst (0.010) - Miss -7.1%
6/6 Veru Inc (NASDAQ: VERU) was given a new $5.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -6.3%
8/1 Veru to Report Fiscal 2019 Third-Quarter Financial Results; Host Conference Call on August 8th -6.3%
1/28 Form DEF 14A VERU INC. For: Mar 24 -5.4%
1/25 Veru Inc (NASDAQ: VERU) was downgraded by analysts at BidaskClub from a "strong-buy" rating to a "buy" rating. -5.4%
1/13 Veru's experimental drug reduces hot flashes in men in mid-stage study [Reuters (UK)] -3.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: